Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function

Cytokine

Volumn 55, Issue 3, 2011, Pages 435-440

  Wanninger, Josef ^a   Weigert, Johanna ^a   Wiest, Reiner ^a   Bauer, Sabrina ^a   Karrasch, Thomas ^a   Farkas, Stefan ^a   Scherer, Marcus N ^a   Walter, Roland ^a   Weiss, Thomas S ^a   Hellerbrand, Claus ^a   Neumeier, Markus ^a   Schäffler, Andreas ^a   Buechler, Christa ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Galectin 3; Hepatic vein; Liver cirrhosis; Portal vein

Indexed keywords

ANTITHROMBIN III; CREATININE; GALECTIN 3; UREA;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LIVER CELL; LIVER FUNCTION; LIVER VEIN; MALE; PORTAL VEIN BLOOD; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UPREGULATION; VENOUS PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBINS; ASCITES; CREATININE; FEMALE; GALECTIN 3; HEPATIC VEINS; HEPATOCYTES; HUMANS; IMMUNOBLOTTING; KIDNEY; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; UREA;

EID: 79960889883     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.06.001     Document Type: Article

References (34)

1. Dumic J., Dabelic S., Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006, 1760:616-635.
2. Lippert E., Gunckel M., Brenmoehl J., Bataille F., Falk W., Scholmerich J., et al. Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation. Clin Exp Immunol 2008, 152:285-297.
3. Nomoto K., Tsuneyama K., Abdel Aziz H.O., Takahashi H., Murai Y., Cui Z.G., et al. Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J Pathol 2006, 210:469-477.
4. Hsu D.K., Dowling C.A., Jeng K.C., Chen J.T., Yang R.Y., Liu F.T. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999, 81:519-526.
5. Henderson N.C., Mackinnon A.C., Farnworth S.L., Poirier F., Russo F.P., Iredale J.P., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006, 103:5060-5065.
6. Weigert J., Neumeier M., Bauer S., Mages W., Schnitzbauer A.A., Obed A., et al. Small-interference RNA-mediated knock-down of aldehyde oxidase 1 in 3T3-L1 cells impairs adipogenesis and adiponectin release. FEBS Lett 2008, 582:2965-2972.
7. Vlassara H., Li Y.M., Imani F., Wojciechowicz D., Yang Z., Liu F.T., et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995, 1:634-646.
8. Beisswenger P.J., Szwergold B.S., Yeo K.T. Glycated proteins in diabetes. Clin Lab Med 2001, 21:53-78.
9. Kalousova M., Zima T., Popov P., Spacek P., Braun M., Soukupova J., et al. Advanced glycation end-products in patients with chronic alcohol misuse. Alcohol Alcohol 2004, 39:316-320.
10. Iwamoto K., Kanno K., Hyogo H., Yamagishi S., Takeuchi M., Tazuma S., et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 2008, 43:298-304.
11. Nakanishi Y., Tsuneyama K., Nomoto K., Fujimoto M., Salunga T.L., Nakajima T., et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res 2008, 38:1241-1251.
12. Weigert J., Neumeier M., Wanninger J., Bauer S., Farkas S., Scherer M.N., et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010, 95:1404-1411.
13. Jiao J., Friedman S.L., Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009, 25:223-229.
14. Moller S., Henriksen J.H., Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int 2008, 2:416-428.
15. Rossle M., Haag K., Ochs A., Sellinger M., Noldge G., Perarnau J.M., et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994, 330:165-171.
16. Weigert J., Neumeier M., Wanninger J., Filarsky M., Bauer S., Wiest R., et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010, 72:342-348.
17. Wiest R., Weigert J., Wanninger J., Neumeier M., Bauer S., Schmidhofer S., et al. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis. Cytokine 2010, 53:178-183.
18. Thasler W.E., Weiss T.S., Schillhorn K., Stoll P.T., Irrgang B., Jauch K.W. Charitable state-controlled foundation human tissue and cell research: ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 2003, 4:49-56.
19. Weber M., Sporrer D., Weigert J., Wanninger J., Neumeier M., Wurm S., et al. Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes. FEBS Lett 2009, 583:3718-3724.
20. MacKinnon A.C., Farnworth S.L., Hodkinson P.S., Henderson N.C., Atkinson K.M., Leffler H., et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008, 180:2650-2658.
21. Durand F., Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008, 28:110-122.
22. Sundblad V., Croci D.O., Rabinovich G.A. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues. Histol Histopathol 2011, 26:247-265.
23. Matsuda Y., Yamagiwa Y., Fukushima K., Ueno Y., Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 2008, 38:1098-1111.
24. Iacovazzi P.A., Notarnicola M., Caruso M.G., Guerra V., Frisullo S., Altomare D.F., et al. Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacol Immunotoxicol 2010, 32:160-164.
25. Koopmann J., Thuluvath P.J., Zahurak M.L., Kristiansen T.Z., Pandey A., Schulick R., et al. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004, 101:1609-1615.
26. Balasubramanian K., Vasudevamurthy R., Venkateshaiah S.U., Thomas A., Vishweshwara A., Dharmesh S.M. Galectin-3 in urine of cancer patients: stage and tissue specificity. J Cancer Res Clin Oncol 2009, 135:355-363.
27. Iacobini C., Menini S., Oddi G., Ricci C., Amadio L., Pricci F., et al. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. Faseb J 2004, 18:1773-1775.
28. Pluta A., Gutkowski K., Hartleb M. Coagulopathy in liver diseases. Adv Med Sci 2010, 55:16-21.
29. Gines P., Guevara M., Arroyo V., Rodes J. Hepatorenal syndrome. Lancet 2003, 362:1819-1827.
30. Sola E., Gines P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010, 53:1135-1145.
31. Bichara M., Attmane-Elakeb A., Brown D., Essig M., Karim Z., Muffat-Joly M., et al. Exploring the role of galectin 3 in kidney function: a genetic approach. Glycobiology 2006, 16:36-45.
32. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12:826-832.
33. Groschel B., Braner J.J., Funk M., Linde R., Doerr H.W., Cinatl J., et al. Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein in HIV-1-infected children. J Clin Immunol 2000, 20:117-122.
34. King R.D., Lubinski J.M., Friedman H.M. Herpes simplex virus type 1 infection increases the carbohydrate binding activity and the secretion of cellular galectin-3. Arch Virol 2009, 154:609-618.